(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

TG THROMBOGENICS

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

TG THROMBOGENICS

ST13

US500000079093385

Classe

1, 5, 42, 44

Pedido

79093385

Registro

4047607

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

42

Atualização mais recente

27/02/2026

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

1, 5, 42, 44

Data de depósito

30/11/2010

Data de registro

01/11/2011

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

13/05/2022

Última transação

27/02/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

99

Localização do titular

BE

Examinador

RUTLAND, BARBARA A

Unidade examinadora

L10

Descrição da marca

The mark consists of the letters "TG" in grey and the word "thrombogenics" in red with a grey vertical line separating the literal elements of the mark.

Titulares e representantes

Titulares

Oxurion NV
ThromboGenics NV

Representantes

Thomas J. Mango Cantor Colburn LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Chemical preparations and substances for use in the manufacture of pharmaceuticals

Classe 5

Pharmaceutical preparations for treatment of diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammalians, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters; material for stopping teeth, dental wax; disinfectants for medical instruments, for hygienic purposes, and for use in medical surgery procedures; preparations for destroying vermin; fungicides, herbicides; biopharmaceutical preparations, namely, anticoagulants, anti angiogenic drugs, anticancer drugs, cardiovascular drugs, protease enzymes, protease inhibitors, antibodies, plasmins, truncated plasmins, microplasmins, plasminogens, truncated plasminogens, microplasminogens, plasminogen activators, staphylokinases for the treatment diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; diagnostic medical reagents, chemicals and biological materials, namely, antigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodies, buffers, and reagents for medical laboratory use in disease testing

Classe 42

Scientific and technological services, namely, scientific research and design of new products in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention, and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; pharmaceutical, biopharmaceutical, medical, biomedical, biological, biochemical, toxicological and clinical research and product development of diagnostic tests and kits, biopharmaceutical preparations and drugs, and medicines; biopharmaceutical product evaluation; biological, biochemical, pharmaceutical, medical, toxicological and clinical research, scientific research for medical purposes in the treatment of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugs, preparations and medicines for ophthalmic, vascular and cancer pathologies

Classe 44

Medical services; veterinary services; medical, veterinary and pharmaceutical advisory and consultancy services; medical services, namely, therapeutic, prognostic and diagnostic testing services

Publicações

Histórico de despachos e eventos da marca no USPTO.

42 publicações encontradas

NREP

NEW REPRESENTATIVE AT IB RECEIVED

26/02/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

08/01/2026

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

11/04/2023

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

01/03/2023

INPC

INVALIDATION PROCESSED

01/03/2023

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

13/01/2023

C71T

CANCELLED SECTION 71

13/05/2022

RNWL

INTERNATIONAL REGISTRATION RENEWED

17/12/2020

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

01/11/2020

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

13/06/2019

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

08/03/2019

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

26/01/2019

INPC

INVALIDATION PROCESSED

26/01/2019

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

11/01/2019

NREP

NEW REPRESENTATIVE AT IB RECEIVED

28/09/2018

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

11/05/2018

71.P

REGISTERED - PARTIAL SEC 71 ACCEPTED

11/05/2018

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/05/2018

ES71

TEAS SECTION 71 RECEIVED

01/05/2018

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

28/07/2012

FICS

FINAL DISPOSITION NOTICE SENT TO IB

08/06/2012

FIMP

FINAL DISPOSITION PROCESSED

08/06/2012

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

01/02/2012

R.PR

REGISTERED-PRINCIPAL REGISTER

01/11/2011

PUBO

PUBLISHED FOR OPPOSITION

16/08/2011

NPUB

NOTICE OF PUBLICATION

27/07/2011

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

13/07/2011

ALIE

ASSIGNED TO LIE

12/07/2011

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

18/06/2011

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

17/06/2011

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

17/06/2011

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

17/06/2011

RFNT

REFUSAL PROCESSED BY IB

09/04/2011

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

22/03/2011

RFRR

REFUSAL PROCESSED BY MPU

22/03/2011

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

19/03/2011

CNRT

NON-FINAL ACTION WRITTEN

18/03/2011

MAFR

APPLICATION FILING RECEIPT MAILED

12/03/2011

DOCK

ASSIGNED TO EXAMINER

08/03/2011

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/03/2011

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

04/03/2011

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

03/03/2011

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace TG THROMBOGENICS ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.